Form 4: Mineralys Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Jon Congleton, Chief Executive Officer and a Director of Mineralys Therapeutics, Inc., sold 10,700 shares of common stock on July 13, 2026 for $27.24 per share.
Summary
- Open-market sale: disposed of 10,700 Common Stock at $27.24 ($291,441) on July 13, 2026; holds 603,621 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $291,441 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jon Congleton — Director, Officer (Chief Executive Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-13 | Open-market sale | Common Stock | 10,700 | $27 | $291.4K | 603,621 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-13 | Open-market sale (10,700 shares) |
Keywords
insider transaction, Form 4, MLYS, Mineralys Therapeutics, Inc., bearish, Jon Congleton
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.